Nama's AI scorecard currently rates Surgery Partners Sell (3.4 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is SGRY's P/E ratio?

Surgery Partners trades at a trailing price-to-earnings ratio of 72.5.

When does SGRY report earnings?

Surgery Partners's next scheduled report is on Nov 9, 2026. Analysts expect EPS of $0.12.

What is the SGRY price target?

The median analyst price target from 5 analysts is $23.50, with a range of $19.00 – $23.50.

Is SGRY Shariah compliant?

Nama's AAOIFI-style screen reads Surgery Partners as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Surgery Partners (SGRY)

Healthcare · Medical Care Facilities · NASDAQ

Surgery Partners (SGRY) is a Healthcare company in the Medical Care Facilities industry. It has a market capitalization of $2.99B, a trailing price-to-earnings ratio of 72.5 and a free-cash-flow yield of 6.6%. Over the most recent reported fiscal year, revenue grew 6.2% and free cash flow per share fell 7.5%. Nama's AI scorecard rates it Sell, 3.4 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Sell · 3.4/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Lagging · -36.6% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-63.7%

How far the last close sits under the highest price of the past five years.

Market cap	$2.99B
Trailing P/E	72.5
Price / book	1.8
Price / sales	0.9
FCF yield	6.6%
Dividend yield	—
Gross margin	22.5%
Operating margin	13.7%
Net margin	-2.6%
Revenue growth (YoY)	+6.2%
Revenue growth (3-yr annual)	+9.2%
EPS growth (YoY)	-51.1%
FCF/share growth (YoY)	-7.5%
Beta	1.9
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Care Facilities

SGRY earnings

Next report: Nov 9, 2026 (Q3 2026, EPS estimate $0.12). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 10, 2026	$0.10	$0.06	+66.7%	$848.90M
Q1 2026	May 5, 2026	-$0.03	-$0.14	+78.6%	$810.90M
Q4 2025	Mar 2, 2026	$0.12	$0.30	-60.0%	$885.00M
Q3 2025	Nov 10, 2025	$0.13	$0.16	-18.8%	$821.50M

SGRY analyst price target

Median target $23.50 from 5 analysts, ranging $19.00 – $23.50.

Medical Care Facilities peers

Ticker	Company	Market cap	P/E
HCA	HCA Healthcare	$103.40B	16.5
THC	Tenet Healthcare	$22.55B	12.7
EHC	Encompass Health	$13.50B	22.4
FMS	Fresenius Medical Care	$12.15B	10.2
DVA	DaVita	$12.04B	13.6
UHS	Universal Health Services	$11.52B	8.6
ENSG	Ensign Group	$10.56B	23.8
PACS	PACS Group	$7.87B	20.1

Explore live SGRY data on Nama Insights →

SGRY FAQ

Is SGRY a buy?: Nama's AI scorecard currently rates Surgery Partners Sell (3.4 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is SGRY's P/E ratio?: Surgery Partners trades at a trailing price-to-earnings ratio of 72.5.
When does SGRY report earnings?: Surgery Partners's next scheduled report is on Nov 9, 2026. Analysts expect EPS of $0.12.
What is the SGRY price target?: The median analyst price target from 5 analysts is $23.50, with a range of $19.00 – $23.50.
Is SGRY Shariah compliant?: Nama's AAOIFI-style screen reads Surgery Partners as Not Shariah Compliant. At least one of the three ratios or the industry test failed.